Matching articles for "Epidiolex"
Fenfluramine (Fintepla) for Dravet Syndrome
The Medical Letter on Drugs and Therapeutics • August 9, 2021; (Issue 1630)
The FDA has approved fenfluramine oral solution
(Fintepla – Zogenix) for treatment of seizures in
patients ≥2 years old with Dravet syndrome. It is the
third drug to be approved for this indication....
The FDA has approved fenfluramine oral solution
(Fintepla – Zogenix) for treatment of seizures in
patients ≥2 years old with Dravet syndrome. It is the
third drug to be approved for this indication. Stiripentol
(Diacomit) and cannabidiol (Epidiolex), a purified
product derived from marijuana, were approved earlier.
Stiripentol (Diacomit) for Dravet Syndrome (online only)
The Medical Letter on Drugs and Therapeutics • March 24, 2021; (Issue 1620)
The FDA has approved stiripentol (Diacomit – Biocodex)
for treatment of seizures in patients ≥2 years old with
Dravet syndrome who are also taking clobazam (Onfi).
Stiripentol, which has been available...
The FDA has approved stiripentol (Diacomit – Biocodex)
for treatment of seizures in patients ≥2 years old with
Dravet syndrome who are also taking clobazam (Onfi).
Stiripentol, which has been available in Europe, Canada,
and Japan for many years, is the second drug to be
approved in the US for this indication; cannabidiol oral
solution (Epidiolex), a purified marijuana product, was
the first.
Cannabis and Cannabinoids
The Medical Letter on Drugs and Therapeutics • November 18, 2019; (Issue 1585)
Cannabis (marijuana) contains more than 60
pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
are the best known. THC is the main psychoactive
constituent of...
Cannabis (marijuana) contains more than 60
pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
are the best known. THC is the main psychoactive
constituent of cannabis. CBD, unlike THC, does not
produce intoxication or euphoria.
Cannabidiol (Epidiolex) for Epilepsy
The Medical Letter on Drugs and Therapeutics • November 5, 2018; (Issue 1559)
The FDA has approved cannabidiol oral solution
(Epidiolex – Greenwich Biosciences) for treatment
of seizures associated with Dravet syndrome or
Lennox-Gastaut syndrome in patients ≥2 years...
The FDA has approved cannabidiol oral solution
(Epidiolex – Greenwich Biosciences) for treatment
of seizures associated with Dravet syndrome or
Lennox-Gastaut syndrome in patients ≥2 years old.
Cannabidiol (CBD) is a cannabinoid constituent of
the marijuana plant (Cannabis sativa). It is the first
natural marijuana product to be approved by the FDA
for any indication and the first drug to be approved in
the US for treatment of Dravet syndrome. Stiripentol
(Diacomit), which is not a marijuana product, was also
recently approved by the FDA for treatment of Dravet
syndrome in combination with clobazam (Onfi) and
will be reviewed in a future issue.
Cannabis and Cannabinoids
The Medical Letter on Drugs and Therapeutics • August 1, 2016; (Issue 1500)
In the US, 25 states and the District of Columbia now
permit some medical use of botanical marijuana
(Cannabis sativa). It has been used for centuries to treat
various ailments, but non-standardization of...
In the US, 25 states and the District of Columbia now
permit some medical use of botanical marijuana
(Cannabis sativa). It has been used for centuries to treat
various ailments, but non-standardization of dosage
makes available data difficult to interpret. Cannabis
contains >60 pharmacologically active cannabinoids.